Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [¹⁴C]-LY4515100 Oral Solution, LY4515100 via SAD, LY4515100 via MAD
LY4515100 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| LY4515100 | EXPERIMENTAL | Administered Orally |
| Placebo | PLACEBO_COMPARATOR | Administered Orally |
| Name | Type | Description |
|---|---|---|
| LY4515100 | DRUG | Administered Orally |
| Placebo | DRUG | Administered Orally |
Inclusion Criteria: * Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive. * Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray. Exclusion...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
LY4515100 is an investigational small molecule being developed by Eli Lilly and Company for the treatment of acute pain. It is currently in Phase 2 clinical development and is not yet approved for any indication. The program includes a placebo-controlled trial in participants experiencing pain following third molar removal.
LY4515100 is being studied for the treatment of acute pain. The only listed clinical trial evaluates it in participants with pain following third molar removal surgery. It is an investigational therapy in Phase 2 development and has not been approved for use in any indication.
LY4515100 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 2 clinical program evaluating the drug in acute pain following third molar removal.
LY4515100 is in Phase 2 clinical development. It is an investigational small molecule and is not FDA approved. The Phase 2 trial is currently recruiting participants, and no trials for this drug have been completed.
LY4515100 is being evaluated in one clinical trial, NCT07511816, titled A Study of LY4515100 in Participants With Pain Following Third Molar Removal. The Phase 2 trial is recruiting, is randomized, double-blind, and placebo-controlled, and plans to enroll 212 participants in the United States.
Yes. [14C]-LY4515100 Oral Solution, LY4515100 via SAD, and LY4515100 via MAD are alternative names used for LY4515100. These names refer to the same investigational small molecule being developed by Eli Lilly and Company for acute pain.